You just read:

Eli Lilly's Taltz Now Approved for Psoriatic Arthritis, Bringing Key Competition for Rival IL-17 Inhibitor, Novartis' Cosentyx

News provided by

Spherix Global Insights

Dec 04, 2017, 15:31 ET